Recent News

• 09.08.2025 - IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
• 09.08.2025 - IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma
• 09.07.2025 - IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer
• 09.04.2025 - IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer
• 09.03.2025 - IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors
• 09.02.2025 - Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
• 08.29.2025 - IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
• 08.29.2025 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 08.25.2025 - IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events
• 08.18.2025 - IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025

Recent Filings

• 09.08.2025 - 8-K Current report
• 09.02.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.05.2025 - 8-K Current report
• 08.05.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 08.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2025 - EX-99.1 EX-99.1